$27.04
2.70% yesterday
Nasdaq, Jul 28, 10:00 pm CET
ISIN
BMG5269C1010
Symbol
KNSA

Kiniksa Pharmaceuticals Ltd. Class A Stock price

$27.04
-0.63 2.28% 1M
+6.86 33.99% 6M
+7.26 36.70% YTD
+0.90 3.44% 1Y
+16.75 162.78% 3Y
+6.95 34.59% 5Y
+7.57 38.88% 10Y
+7.57 38.88% 20Y
Nasdaq, Closing price Mon, Jul 28 2025
+0.71 2.70%
ISIN
BMG5269C1010
Symbol
KNSA
Industry

Key metrics

Basic
Market capitalization
$1.9b
Enterprise Value
$1.7b
Net debt
positive
Cash
$268.3m
Shares outstanding
72.8m
Valuation (TTM | estimate)
P/E
negative | 35.6
P/S
4.0 | 3.3
EV/Sales
3.4 | 2.8
EV/FCF
37.8
P/B
4.2
Financial Health
Equity Ratio
75.5%
Return on Equity
-9.9%
ROCE
-3.2%
ROIC
-13.6%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$481.2m | $580.7m
EBITDA
$-14.2m | $61.4m
EBIT
$-15.8m | $40.4m
Net Income
$-17.0m | $53.8m
Free Cash Flow
$43.7m
Growth (TTM | estimate)
Revenue
59.5% | 37.2%
EBITDA
49.8% | 239.8%
EBIT
48.3% | 188.5%
Net Income
-296.0% | 224.7%
Free Cash Flow
104.7%
Margin (TTM | estimate)
Gross
85.8%
EBITDA
-3.0% | 10.6%
EBIT
-3.3%
Net
-3.5% | 9.3%
Free Cash Flow
9.1%
More
EPS
$-0.2
FCF per Share
$0.6
Short interest
6.5%
Employees
315
Rev per Employee
$1.3m
Show more

Is Kiniksa Pharmaceuticals Ltd. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Kiniksa Pharmaceuticals Ltd. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Kiniksa Pharmaceuticals Ltd. Class A forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Kiniksa Pharmaceuticals Ltd. Class A forecast:

Buy
92%
Hold
8%

Financial data from Kiniksa Pharmaceuticals Ltd. Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
481 481
59% 59%
100%
- Direct Costs 68 68
85% 85%
14%
413 413
56% 56%
86%
- Selling and Administrative Expenses 173 173
24% 24%
36%
- Research and Development Expense 105 105
20% 20%
22%
-14 -14
50% 50%
-3%
- Depreciation and Amortization 1.57 1.57
29% 29%
0%
EBIT (Operating Income) EBIT -16 -16
48% 48%
-3%
Net Profit -17 -17
296% 296%
-4%

In millions USD.

Don't miss a Thing! We will send you all news about Kiniksa Pharmaceuticals Ltd. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kiniksa Pharmaceuticals Ltd. Class A Stock News

Neutral
GlobeNewsWire
5 days ago
LONDON, July 24, 2025 (GLOBE NEWSWIRE) --  Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 29, 2025 at 8:30 a.m. Eastern Time to report its second quarter 2025 financial results and recent portfolio execution.
Positive
The Motley Fool
26 days ago
Explore the exciting world of Kiniksa Pharmaceuticals (KNSA 0.99%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Positive
Investors Business Daily
28 days ago
Biotech stock Kiniksa soared after first-quarter results on April 29. Shares are near a buy point of 28.15.
More Kiniksa Pharmaceuticals Ltd. Class A News

Company Profile

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.

Head office Bermuda
CEO Sanj Patel
Employees 315
Founded 2015
Website www.kiniksa.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today